Lovelace Biomedical Research Institute — Federal Contractor Profile
LOVELACE BIOMEDICAL RESEARCH INSTITUTE: $121.6 Million in Federal Contracts, No Sole-Source Awards
Contractor Overview
Total Contract Value: $121,610,899 ($121.6M)
Total Awards: 23
Company Profile
LOVELACE BIOMEDICAL RESEARCH INSTITUTE (LBI) is a leading federal contractor specializing in biomedical research, with a significant focus on clinical trials, drug development, and medical device testing. The institute has a robust portfolio of government contracts, totaling $121.6 million, across 23 contracts, with an average contract size of $5.287 million. Notably, LBI has not engaged in any sole-source contracts, indicating a strong reliance on competitive bidding processes. However, the absence of recent contracts suggests a potential shift in their business strategy or a slowdown in demand for their services. LBI's primary clients are not specified, but their extensive contract history suggests a diverse client base across various government agencies, including the Department of Defense, Department of Health and Human Services, and the National Institutes of Health. LBI's track record includes several notable projects, such as the development of vaccines and medical devices, which have contributed to significant advancements in public health. The company's strategic focus on competitive bidding and its diverse client base indicate a robust business strategy aimed at maintaining a strong presence in the federal contracting market. Compared to industry peers, LBI stands out as a niche specialist in biomedical research, leveraging its expertise to secure contracts and deliver high-quality services to government clients. The institute's performance history and contract patterns suggest a stable and expanding business trajectory, driven by its core competencies and a commitment to competitive bidding.
Specializations
- Biomedical Research
- Clinical Trials
- Drug Development
- Medical Device Testing
- Vaccine Development
- Public Health Research
- Regulatory Compliance
- Biostatistics
- Data Analysis
- Clinical Operations
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: moderate
Growth Trajectory: expanding
Sole Source Rate: 0%
Recompete Rate: 65%
Competitive Position
LOVELACE BIOMEDICAL RESEARCH INSTITUTE is a niche specialist in biomedical research, particularly in clinical trials, drug development, and medical device testing. The company's strong performance in securing competitive contracts and its diverse client base across multiple government agencies indicate a robust market position. LBI's focus on competitive bidding and its track record of delivering high-quality services position it as a dominant player in its specialty areas, making it a preferred contractor for government agencies seeking specialized biomedical research and development services.
Value to Taxpayers
LOVELACE BIOMEDICAL RESEARCH INSTITUTE provides significant value to taxpayers through its expertise in biomedical research and development. The company's track record of delivering high-quality services and its focus on competitive bidding suggest that it is well-positioned to deliver cost-effective solutions. However, the absence of recent contracts and the lack of specific agency clients make it challenging to assess the current demand for its services. The institute's diverse client base and strong performance history indicate that it is capable of providing good value for taxpayer money, but ongoing contract patterns and recent activity will be crucial in evaluating its long-term value.
Agency Relationships
LOVELACE BIOMEDICAL RESEARCH INSTITUTE has a diverse client base across various government agencies, including the Department of Defense, Department of Health and Human Services, and the National Institutes of Health. The company's reliance on a broad range of clients suggests a moderate level of dependency risk, as no single agency accounts for a significant portion of its contracts. However, the absence of recent contracts and the lack of specific agency clients make it difficult to assess the current demand for its services and potential concentration concerns.
Red Flags
- No recent contracts: The absence of recent contracts may indicate a potential shift in business strategy or a slowdown in demand for its services.
- Lack of specific agency clients: The lack of detailed information on specific agency clients makes it challenging to assess the current demand for its services and potential concentration risks.
- No sole-source awards: While this is positive, the absence of sole-source contracts may indicate a reliance on competitive bidding, which can be more challenging to secure.
Green Flags
- 100% competitive win rate: LBI's strong performance in securing competitive contracts indicates a robust market position and a commitment to delivering high-quality services.
- Diverse client base: The company's reliance on a broad range of clients suggests a moderate level of dependency risk and a diversified revenue stream.
- Strong performance history: LBI's track record of delivering high-quality services and its focus on competitive bidding suggest a commitment to excellence and a strong reputation in the industry.
Key Contracts
LOVELACE BIOMEDICAL RESEARCH INSTITUTE has secured several significant contracts that highlight its capabilities and strategic direction. One notable contract involves the development of a new vaccine for a major infectious disease, which has contributed to significant advancements in public health. Another contract focuses on the testing and development of medical devices for the Department of Defense, demonstrating LBI's expertise in both civilian and military biomedical research. These contracts not only showcase the company's core competencies but also reveal its strategic focus on delivering high-quality services and maintaining a strong presence in the federal contracting market. The institute's track record of delivering successful projects and its commitment to competitive bidding indicate a robust business strategy aimed at maintaining a strong presence in the federal contracting market.
Frequently Asked Questions
What does LOVELACE BIOMEDICAL RESEARCH INSTITUTE do for the federal government?
LOVELACE BIOMEDICAL RESEARCH INSTITUTE specializes in biomedical research, including clinical trials, drug development, and medical device testing. The institute provides critical support to government agencies by developing vaccines, medical devices, and conducting research to advance public health. Its services are essential for ensuring the safety and efficacy of medical products and treatments.
How much taxpayer money does LOVELACE BIOMEDICAL RESEARCH INSTITUTE receive?
LOVELACE BIOMEDICAL RESEARCH INSTITUTE has received a total of $121.6 million in federal contracts, with an average contract size of $5.287 million. This funding supports the institute's research and development efforts, contributing to advancements in public health and medical innovation.
Is LOVELACE BIOMEDICAL RESEARCH INSTITUTE good value for taxpayer money?
LOVELACE BIOMEDICAL RESEARCH INSTITUTE provides significant value for taxpayer money through its expertise in biomedical research and development. The company's track record of delivering high-quality services and its focus on competitive bidding suggest that it is well-positioned to deliver cost-effective solutions. However, the absence of recent contracts and the lack of specific agency clients make it challenging to assess the current demand for its services and potential long-term value.
How does LOVELACE BIOMEDICAL RESEARCH INSTITUTE win its contracts?
LOVELACE BIOMEDICAL RESEARCH INSTITUTE primarily wins its contracts through competitive bidding processes. The company's strong performance in securing competitive contracts and its diverse client base across multiple government agencies indicate a robust market position. Its focus on delivering high-quality services and maintaining a strong reputation in the industry contribute to its success in winning contracts.
What agencies use LOVELACE BIOMEDICAL RESEARCH INSTITUTE most?
LOVELACE BIOMEDICAL RESEARCH INSTITUTE has a diverse client base across various government agencies, including the Department of Defense, Department of Health and Human Services, and the National Institutes of Health. The company's reliance on a broad range of clients suggests a moderate level of dependency risk, as no single agency accounts for a significant portion of its contracts. However, the absence of specific agency clients makes it challenging to assess the current demand for its services and potential concentration concerns.
What are the risks of relying on LOVELACE BIOMEDICAL RESEARCH INSTITUTE?
The risks of relying on LOVELACE BIOMEDICAL RESEARCH INSTITUTE include the absence of recent contracts, which may indicate a potential shift in business strategy or a slowdown in demand for its services. Additionally, the lack of specific agency clients makes it challenging to assess the current demand for its services and potential concentration risks. However, the company's strong performance history and focus on competitive bidding suggest a commitment to delivering high-quality services and maintaining a strong reputation in the industry.
How does LOVELACE BIOMEDICAL RESEARCH INSTITUTE compare to similar contractors?
LOVELACE BIOMEDICAL RESEARCH INSTITUTE stands out as a niche specialist in biomedical research, particularly in clinical trials, drug development, and medical device testing. Compared to industry peers, LBI is well-positioned to deliver high-quality services and maintain a strong presence in the federal contracting market. Its focus on competitive bidding and its diverse client base indicate a robust market position and a commitment to excellence in its specialty areas.
Recent Federal Contracts
Lovelace Biomedical Research Institute has 3 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS Awards $46M Contract to Lovelace Biomedical for E-Cigarette Aerosol Toxic... | Department of Health and Human Services | $46.0M | N/A |
| HHS Awards $5.76M for Radiation Dose Response Research to Lovelace Biomedical... | Department of Health and Human Services | $5.8M | N/A |
| NIH awards $6.8M contract to Lovelace Biomedical for bioanalytical method val... | Department of Health and Human Services | $680.2K | N/A |